What is the role of nonpharmacologic therapy in the treatment of sarcoidosis?

1. Caplan A, Rosenbach M, Imadojemu S. Cutaneous Sarcoidosis. Semin Respir Crit Care Med. 2020 Oct. 41 (5):689-699. [Medline].

2. Caso F, Costa L, Rigante D, et al. Caveats and truths in genetic, clinical, autoimmune and autoinflammatory issues in Blau syndrome and early onset sarcoidosis. Autoimmun Rev. 2014 Aug 23. [Medline].

3. Caso F, Galozzi P, Costa L, Sfriso P, Cantarini L, Punzi L. Autoinflammatory granulomatous diseases: from Blau syndrome and early-onset sarcoidosis to NOD2-mediated disease and Crohn's disease. RMD Open. 2015. 1 (1):e000097. [Medline].

4. Hunt RD, Gonzalez ME, Robinson M, Meehan SA, Franks AG Jr. Ulcerative sarcoidosis. Dermatol Online J. 2012 Dec 15. 18(12):29. [Medline].

5. Pellicano R, Tiodorovic-Zivkovic D, Gourhant JY, Catricala C, Ferrara G, Caldarola G. Dermoscopy of cutaneous sarcoidosis. Dermatology. 2010 Aug. 221(1):51-4. [Medline].

6. Fancher W, Braniecki M, Guzman G, Groth J, Krunic A. Disseminated atrophic sarcoidosis with elastophagocytosis and elastic tissue loss. Br J Dermatol. 2014 Sep 16. [Medline].

7. Nishizawa A, Igawa K, Teraki H, Yokozeki H. Diffuse disseminated lichenoid-type cutaneous sarcoidosis mimicking erythroderma. Int J Dermatol. 2014 Aug. 53(8):e369-70. [Medline].

8. Jorizzo JL, Koufman JA, Thompson JN, White WL, Shar GG, Schreiner DJ. Sarcoidosis of the upper respiratory tract in patients with nasal rim lesions: a pilot study. J Am Acad Dermatol. 1990 Mar. 22(3):439-43. [Medline].

9. Marcoval J, Maña J, Moreno A, Peyri J. Subcutaneous sarcoidosis--clinicopathological study of 10 cases. Br J Dermatol. 2005 Oct. 153(4):790-4. [Medline].

10. Ahmed I, Harshad SR. Subcutaneous sarcoidosis: is it a specific subset of cutaneous sarcoidosis frequently associated with systemic disease?. J Am Acad Dermatol. 2006 Jan. 54(1):55-60. [Medline].

11. Tchernev G. Cutaneous sarcoidosis: the "great imitator": etiopathogenesis, morphology, differential diagnosis, and clinical management. Am J Clin Dermatol. 2006. 7(6):375-82. [Medline].

12. Cather JC, Cohen PR. Ichthyosiform sarcoidosis. J Am Acad Dermatol. 1999 May. 40(5 Pt 2):862-5. [Medline].

13. Antonovich DD, Callen JP. Development of sarcoidosis in cosmetic tattoos. Arch Dermatol. 2005 Jul. 141(7):869-72. [Medline].

14. Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, Goldinger SM, Barysch M, et al. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res. 2018 Jun. 28 (3):230-236. [Medline].

15. Tchernev G, Lotti T, Wollina U, Cardoso JC, Popova LV, Maximov GK, et al. Sarcoidosis in A. C. Milan (1899)?. Open Access Maced J Med Sci. 2018 Jan 25. 6 (1):99-102. [Medline].

16. Terziroli Beretta-Piccoli B, Mainetti C, Peeters MA, Laffitte E. Cutaneous Granulomatosis: a Comprehensive Review. Clin Rev Allergy Immunol. 2018 Feb. 54 (1):131-146. [Medline].

17. Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy. Am J Clin Dermatol. 2018 Jun. 19 (3):345-361. [Medline].

18. Garcia-Porrua C, Gonzalez-Gay MA, Garcia-Pais MJ, Blanco R. Cutaneous vasculitis: an unusual presentation of sarcoidosis in adulthood. Scand J Rheumatol. 1998. 27(1):80-2. [Medline].

19. Doherty CB, Rosen T. Evidence-based therapy for cutaneous sarcoidosis. Drugs. 2008. 68(10):1361-83. [Medline].

20. Gedalia A, Molina JF, Ellis GS Jr, Galen W, Moore C, Espinoza LR. Low-dose methotrexate therapy for childhood sarcoidosis. J Pediatr. 1997 Jan. 130(1):25-9. [Medline].

21. Lower EE, Baughman RP. Prolonged use of methotrexate for sarcoidosis. Arch Intern Med. 1995 Apr 24. 155(8):846-51. [Medline].

22. Webster GF, Razsi LK, Sanchez M, Shupack JL. Weekly low-dose methotrexate therapy for cutaneous sarcoidosis. J Am Acad Dermatol. 1991 Mar. 24(3):451-4. [Medline].

23. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol. 1990 Sep. 23(3 Pt 1):487-9. [Medline].

24. Baughman RP, Lower EE. Steroid-sparing alternative treatments for sarcoidosis. Clin Chest Med. 1997 Dec. 18(4):853-64. [Medline].

25. Stagaki E, Mountford WK, Lackland DT, Judson MA. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Chest. 2009 Feb. 135(2):468-76. [Medline].

26. Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013 May. 68(5):765-73. [Medline].

27. Judson MA, Baughman RP, Costabel U, et al. Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. Eur Respir J. 2014 Jul 17. [Medline].

28. Heidelberger V, Ingen-Housz-Oro S, Marquet A, et al. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. JAMA Dermatol. 2017 Jul 1. 153 (7):681-685. [Medline].

29. Park SK, Hwang PH, Yun SK, Kim HU, Park J. Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature. Ann Dermatol. 2017 Feb. 29 (1):74-78. [Medline].

30. Tu J, Chan J. Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease. Australas J Dermatol. 2013 May 8. [Medline].

31. Philips MA, Lynch J, Azmi FH. Ulcerative cutaneous sarcoidosis responding to adalimumab. J Am Acad Dermatol. 2005 Nov. 53(5):917. [Medline].

32. Pariser RJ, Paul J, Hirano S, Torosky C, Smith M. A double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis. J Am Acad Dermatol. 2013 May. 68(5):765-73. [Medline].

33. Kiorpelidou D, Gaitanis G, Zioga A, Bassukas ID. Short course of infliximab for disfiguring lupus pernio. Eur J Dermatol. 2008 Nov-Dec. 18(6):727-9. [Medline].

34. Kataria YP. Chlorambucil in sarcoidosis. Chest. 1980 Jul. 78(1):36-43. [Medline].

35. Waldinger TP, Ellis CN, Quint K, Voorhees JJ. Treatment of cutaneous sarcoidosis with isotretinoin. Arch Dermatol. 1983 Dec. 119(12):1003-5. [Medline].

36. Brechtel B, Haas N, Henz BM, Kolde G. Allopurinol: a therapeutic alternative for disseminated cutaneous sarcoidosis. Br J Dermatol. 1996 Aug. 135(2):307-9. [Medline].

37. Inoue Y, Teraki Y. Association of Propionibacterium acnes with the efficacy of minocycline therapy for cutaneous sarcoidosis. Int J Dermatol. 2020 Jun. 59 (6):704-708. [Medline].

38. Bachelez H, Senet P, Cadranel J, Kaoukhov A, Dubertret L. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol. 2001 Jan. 137(1):69-73. [Medline].

39. Baughman RP, Judson MA, Lower EE, Drent M, Costabel U, Flavin S, et al. Infliximab for chronic cutaneous sarcoidosis: a subset analysis from a double-blind randomized clinical trial. Sarcoidosis Vasc Diffuse Lung Dis. 2016 Jan 15. 32 (4):289-95. [Medline].

40. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol. 2005 Jul. 141(7):910-1. [Medline].

41. Carlesimo M, Giustini S, Rossi A, Bonaccorsi P, Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J Am Acad Dermatol. 1995 May. 32(5 Pt 2):866-9. [Medline].

42. Kalajian AH, Van Meter JR, Callen JP. Sarcoidal anemia and leukopenia treated with methotrexate and mycophenolate mofetil. Arch Dermatol. 2009 Aug. 145(8):905-9. [Medline].

43. Kouba DJ, Mimouni D, Rencic A, Nousari HC. Mycophenolate mofetil may serve as a steroid-sparing agent for sarcoidosis. Br J Dermatol. 2003 Jan. 148(1):147-8. [Medline].

44. Damsky W, Young BD, Sloan B, Miller EJ, Obando JA, King B. Treatment of Multiorgan Sarcoidosis With Tofacitinib. ACR Open Rheumatol. 2020 Feb. 2 (2):106-109. [Medline].

45. Saylam Kurtipek G, Ataseven A, Kurtipek E, Kucukosmanoglu İ, Toksoz MR. Resolution of Cutaneous Sarcoidosis Following Topical Application of Ganoderma lucidum (Reishi Mushroom). Dermatol Ther (Heidelb). 2016 Mar. 6 (1):105-9. [Medline].

46. Zhu X, Sun J. A case of facial atrophic sarcoidosis in an adolescent, successfully treated with the combination of prednisone and hydroxychloroquine. An Bras Dermatol. 2020 May - Jun. 95 (3):340-342. [Medline].

47. Lee JB, Koblenzer PS. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. J Am Acad Dermatol. 1998 Nov. 39(5 Pt 2):835-8. [Medline].

48. Rousseau L, Beylot-Barry M, Doutre MS, Beylot C. Cutaneous sarcoidosis successfully treated with low doses of thalidomide. Arch Dermatol. 1998 Aug. 134(8):1045-6. [Medline].

49. Gharavi N, Diehl J, Soriano T. Cutaneous Sarcoidosis Successfully Treated With Intralesional 5-Fluorouracil. Dermatol Surg. 2015 Sep. 41 (9):1082-5. [Medline].

50. Fazzi P. Pharmacotherapeutic management of pulmonary sarcoidosis. Am J Respir Med. 2003. 2(4):311-20. [Medline].

51. Kaura V, Kaura SH, Kaura CS. ACE Inhibitor in the treatment of cutaneous and lymphatic sarcoidosis. Am J Clin Dermatol. 2007. 8(3):183-6. [Medline].

52. Wilsmann-Theis D, Bieber T, Novak N. Photodynamic therapy as an alternative treatment for cutaneous sarcoidosis. Dermatology. 2008. 217(4):343-6. [Medline].

Joseph F Merola, MD, MMSc Assistant Professor of Dermatology, Harvard Medical School; Director of Clinical Trials for Dermatology, Co-Director, Center for Skin and Related Musculoskeletal Diseases, Department of Dermatology and Department of Medicine, Division of Rheumatology, Associate Program Director, Combined Medicine-Dermatology Residency Program, Brigham and Women's Hospital

Joseph F Merola, MD, MMSc is a member of the following medical societies: American Academy of Dermatology, American College of Rheumatology, Massachusetts Medical Society, Medical Dermatology Society, Rheumatologic Dermatology Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: Consultant and/or investigator for Merck, Abbvie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres and Leo Pharma.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received honoraria from UpToDate for author/editor; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; I serve on a safety monitoring committee for Principia Biopharma for: Allergen; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Michael J Wells, MD, FAAD Dermatologic/Mohs Surgeon, The Surgery Center at Plano Dermatology

Michael J Wells, MD, FAAD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Texas Medical Association

Disclosure: Nothing to disclose.

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Ponciano D Cruz, Jr, MD Professor and Vice-Chair, Paul R Bergstresser Chair, Department of Dermatology, University of Texas Southwestern Medical Center

Ponciano D Cruz, Jr, MD is a member of the following medical societies: Texas Medical Association

Disclosure: Received consulting fee from RCTS for independent contractor; Received honoraria from Mary Kay Cosmetics for consulting; Received grant/research funds from Galderma for principal investigator.

Karen Podlipsky Gould, MD Physician, Private Practice

Karen Podlipsky Gould, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.